Patent ID: 9023795
Filing Date: 2015-05-05
Classification: A61K,A61P,C07K

Abstract:
1. A pharmaceutical composition, comprising: (a) a polypeptide as set forth by the following formula I, or a pharmaceutically acceptable salt thereof, wherein, Xaa0 is Cys; Xaa1 is selected from the group consisting of Val or Leu; Xaa2 is selected from the group consisting of Ser or Thr; Xaa3 is selected from the group consisting of Leu, or Ile; Xaa4 is selected from the group consisting of Leu, or Ile; Xaa5 is selected from the group consisting of Arg or Lys; Xaa6 is selected from the group consisting of Cys; Xaa7 is selected from the group consisting of Thr or Ser; Xaa8 is selected from the group consisting of Gly or Ala; Xaa9 is selected from the group consisting of Cys; Xaa10 is selected from the group consisting of Cys; Xaa11 is selected from the group consisting of Gly or Ala; Xaa12 is selected from the group consisting of Asp or Glu; Xaa13 is selected from the group consisting of Glu or Asp; Xaa14 is selected from the group consisting of Asn or Gln; Xaa15 is selected from the group consisting of Leu or Ile; Xaa16 is selected from the group consisting of His or Arg; Xaa17 is selected from the group consisting of Cys; Xaa18 is none, or a peptide segment consisting of 1-3 amino acids, wherein the peptide segment is one of (1) Ala, (2) Val, (3) AlaVal, (4) ValPro, (5) ValProVal, (6) AlaProAla, and (7) ValProAla; and the polypeptide exhibits an activity of inhibiting angiogenesis and has a length of 18-21 amino acids; and (b) a pharmaceutically acceptable carrier or excipient, wherein the polypeptide is present in an amount effective for treating a disease associated with angiogenesis, said disease associated with angiogenesis is selected from the group consisting of neovascular eye disease and a tumor, and wherein the amount is 10 μg to 100 mg.